Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK (ABIRISK)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • Rare disease
  • Disease focus:
    Hemophilia A, Inflammatory Diseases, Multiple Sclerosis
  • Location: Europe


Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK (ABIRISK) is a consortium managed by the Innovative Medicines Initiative (IMI). ABIRISK seeks to provide an integrated approach to anti-drug immunization by evaluating immunogenicity in hemophilia A, multiple sclerosis, and inflammatory diseases, and by exploring new tools for protein drug immunogenicity. By examining the correlation between patient and clinical factors and the incidence of immunogenicity, ABIRISK hopes to reduce the regulatory and resource burdens of immunogenicity testing.


ABIRISK aims to develop an integrated approach to anti-drug immunization through examination of immunogenicity in three other conditions: hemophilia A, multiple sclerosis, and inflammatory diseases. The data collected will be pooled in a single immunogenicity databank and will be standardized and used to develop models of anti-drug antibodies.

The objectives of the consortium are as follows:

Consortium History

2012: ABIRISK was started as a 60-month project.

Structure & Governance

ABIRISK is grouped into five working projects, which communicate with one another and provide each other with results and data for analysis. The five working projects are ADA assay development and validation and cohort management; cellular characterization and mechanisms of the AD immune response; evaluation and development of technologies for predicting immunogenicity; establishment of database, data analyses and integration; and project management and communication. Each working project has three to four team leaders.

As with other IMI-managed consortia, ABRISK project teams are managed by an IMI project manager, who reports to the IMI executive director.


ABIRISK received total funding of £34.9 million, which was broken down into IMI funding (£18.2 million), in-kind funding contributions from the European Federation of Pharmaceutical Industries and Associations (EFPIA; £11.2 million), and £5.5 million from other sources.

Intellectual Property

All IMI projects, such as ABIRISK, operate under the same intellectual property (IP) umbrella. Any IP discovered as a result of work in the collaboration is owned by the participating institution that made the discovery (or if the discovery was made jointly, by both institutions). Other participants have access rights to the generated IP during and after the project for research use, and participant owners have the right to license their IP and associated obligations to other parties, including to affiliated entities. Third parties may request access rights, which do not involve the ability to sublicense without receiving authorization from the IP-owning participant.

Patient Engagement

ABIRISK recruits both retrospective study patients (after patients suffering from the three disease groups have undergone immunotherapy treatment) and prospective patients into dedicated studies. Uniform protocols were established to facilitate standardized data collection from both sets of patients.

Data Sharing

Uniform protocols were established to facilitate standardized data collection from both sets of patients. The intent of ABIRISK is to share its data as quickly as possible through its immunogenicity databank. In keeping with IMI policy, the project has up to one year after completion to disseminate IP or data created by the project.


To date, nine publications have been released from groups associated with the ABIRISK project.

Points of Contact

Project Coordinator:
Daniel Sikkema
GlaxoSmithKline Research & Development Ltd
980 Great West Road, Brentford
Middlesex, TW8 9GS
United Kingdom
phone: (610) 270-6054

Managing Entity for EU funds:
Marc Pallardy
Institut National de la Santé et de la Recherche Médicale
UMR 996, University Paris-Sud
32 rue des Carnets
92140 Clamart
phone: 33-1-46-83-54-92

Sponsors & Partners

Academisch Medisch Centrum

ALTA Ricerca e Sviluppo in Biotecnologie Srlu

Bayer Pharma AG

Biomonitor A/S

Centre National de la Recherche Scientifique

Commissariat a L’Energie Atomique et aux Energies Alternatives

DRK-Blutspendedienst Baden-Württemberg– Hessen gemeinnützige GmbH

Fondazione per I’Istituto di Ricera in Biomedicina

Fundació Institut de Recerca de L'hospital Universitari Vall D’hebron


Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif

Höpitaux de Paris


IPSEN Innovation SAS

Istituto Giannina Gaslini

Johann Wolfgang Goethe Universität

Karolinska Institutet

Klinikum rechts der Isar der Technischen Universität München

Leiden University Medical Center

Medizinische Universität Innsbruck

Merck KGaA

Novartis Pharma AG

Novo Nordisk A/S

Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel

Pfizer Limited

Queen Mary and Westfield, University of London

Rambam Medical Center

Region Hovedstaden


UCB Pharma SA

Universita di Firenze

Universitätsklinikum Bonn

Universitätsklinikum Düsseldorf

University College London

University Hospital Basel

Univerzita Karlova v Praze

Last Updated: 04/06/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.